^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Gastroesophageal Junction Adenocarcinoma

    Related cancers:
    1d
    Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer (clinicaltrials.gov)
    P2, N=100, Recruiting, Jeeyun Lee | N=50 --> 100
    Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
    |
    HER-2 positive • CLDN18.2 positive
    |
    Imfinzi (durvalumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • oxaliplatin • sonesitatug vedotin (AZD0901) • rilvegostomig (AZD2936)
    1d
    Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer (clinicaltrials.gov)
    P2, N=2, Active, not recruiting, National Cancer Institute (NCI) | N=240 --> 2 | Trial completion date: Oct 2027 --> Jun 2027 | Trial primary completion date: Oct 2027 --> Jan 2026
    Enrollment change • Trial completion date • Trial primary completion date • MSI-H • dMMR
    |
    MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
    |
    MSI-H/dMMR
    |
    Tecentriq (atezolizumab) • docetaxel • capecitabine • oxaliplatin • leucovorin calcium • fluorouracil topical
    1d
    FREEDOM: Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer (clinicaltrials.gov)
    P=N/A, N=150, Recruiting, Harbin Medical University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    paclitaxel • docetaxel • albumin-bound paclitaxel • irinotecan • Fruzaqla (fruquintinib)
    2d
    Retlirafusp Alfa Injection Plus Chemotherapy Versus Investigator's Choice of Anti-PD-1 Antibody Plus Chemotherapy as First-line Treatment for Advanced Gastric Cancer With Liver Metastases (clinicaltrials.gov)
    P3, N=332, Not yet recruiting, Peking University
    New P3 trial
    |
    Tyvyt (sintilimab) • Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin • retlirafusp alfa (SHR-1701)
    2d
    Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer (clinicaltrials.gov)
    P1/2, N=186, Recruiting, Zhejiang Doer Biologics Co., Ltd. | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative • HER-2 expression
    |
    5-fluorouracil • capecitabine • oxaliplatin • irinotecan • leucovorin calcium
    3d
    POSIT: Neoadjuvant PD-1 Inhibitor Plus SOX Chemotherapy With or Without Short-Course Radiotherapy for Locally Advanced Upper Gastric or GEJ Adenocarcinoma (clinicaltrials.gov)
    P=N/A, N=146, Not yet recruiting, Tongji Hospital
    New trial • Tumor mutational burden
    |
    PD-L1 (Programmed death ligand 1)
    |
    Hetronifly (serplulimab)
    3d
    Efficacy and Safety of Pembrolizumab as Monotherapy and in Combination with Chemotherapy versus Chemotherapy Alone for Advanced Gastric or Gastroesophageal Junction Cancer: A Systematic Review and Meta-Analysis. (PubMed, Anticancer Agents Med Chem)
    Pembrolizumab combined with chemotherapy is an effective therapeutic strategy for advanced GC/GEJC, whereas monotherapy lacks superior efficacy in the general population and should be interpreted with caution due to observed heterogeneity.
    Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab)
    3d
    Comparative efficacy of tislelizumab + FOLFOX or CAPOX for gastric/gastroesophageal junction adenocarcinoma: an exploratory matching-adjusted indirect comparison. (PubMed, Curr Med Res Opin)
    In the RATIONALE-305 trial, first-line tislelizumab + chemotherapy (CAPOX ([capecitabine + oxaliplatin] or 5-fluorouracil [5-FU] + cisplatin) significantly improved overall and progression-free survival (PFS) versus placebo + chemotherapy in unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric/gastroesophageal junction cancer (GC/GEJC). This exploratory analysis evaluated the comparative efficacy of tislelizumab + CAPOX versus tislelizumab + CAPOX or FOLFOX (5-FU, leucovorin, oxaliplatin) using a matching-adjusted indirect comparison (MAIC) approach...Although median PFS was numerically longer with the mixed chemotherapy backbone, these findings are exploratory in nature and warrant further investigation. ClinicalTrials.gov, RATIONALE-305 (NCT03777657); DisTinGuish (NCT04363801).
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    cisplatin • 5-fluorouracil • Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin • leucovorin calcium
    3d
    Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=500, Recruiting, MediLink Therapeutics (Suzhou) Co., Ltd. | N=155 --> 500 | Trial completion date: Apr 2029 --> Jun 2031 | Trial primary completion date: Apr 2027 --> Jun 2031
    Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed
    3d
    JS107 in Combination With Toripalimab and Chemotherapy for the Treatment of CLDN18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P3, N=600, Recruiting, NingBo Junyan Hongshi Biosciences Co., Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
    |
    HER-2 negative • CLDN18.2 positive
    |
    Tyvyt (sintilimab) • Loqtorzi (toripalimab-tpzi) • capecitabine • oxaliplatin
    3d
    A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer (clinicaltrials.gov)
    P3, N=570, Not yet recruiting, Astellas Pharma Global Development, Inc.
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • CLDN18 (Claudin 18)
    |
    PD-L1 expression • MSI-H/dMMR • HER-2 negative • CLDN18.2 positive
    |
    Keytruda (pembrolizumab) • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • ASP2138
    3d
    Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis (clinicaltrials.gov)
    P1, N=15, Active, not recruiting, Mayo Clinic | Trial completion date: Apr 2030 --> Jun 2029 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial completion date
    |
    Opdivo (nivolumab) • oxaliplatin • leucovorin calcium • Proleukin (aldesleukin) • fluorouracil topical • ABP 206 (nivolumab biosimilar)